Roquefort Therapeutics (ROQ) Competitors GBX 1.36 +0.06 (+4.62%) As of 08/29/2025 11:46 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock ROQ vs. CIZ, TCF, EVG, GENF, MTFB, DEST, BSFA, VAL, RENE, and SALVShould you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Cizzle Biotechnology (CIZ), Theracryf (TCF), Evgen Pharma (EVG), Genflow Biosciences (GENF), Motif Bio (MTFB), Destiny Pharma (DEST), BSF Enterprise (BSFA), ValiRx (VAL), ReNeuron Group (RENE), and SalvaRx Group (SALV). These companies are all part of the "biotechnology" industry. Roquefort Therapeutics vs. Its Competitors Cizzle Biotechnology Theracryf Evgen Pharma Genflow Biosciences Motif Bio Destiny Pharma BSF Enterprise ValiRx ReNeuron Group SalvaRx Group Cizzle Biotechnology (LON:CIZ) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Which has preferable earnings & valuation, CIZ or ROQ? Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCizzle BiotechnologyN/AN/A-£2.81K-£0.01-216.67Roquefort TherapeuticsN/AN/A-£1.52M-£0.01-181.33 Does the media prefer CIZ or ROQ? In the previous week, Roquefort Therapeutics had 1 more articles in the media than Cizzle Biotechnology. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Cizzle Biotechnology. Roquefort Therapeutics' average media sentiment score of 0.26 beat Cizzle Biotechnology's score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cizzle Biotechnology Neutral Roquefort Therapeutics Neutral Is CIZ or ROQ more profitable? Cizzle Biotechnology has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Cizzle Biotechnology's return on equity of -0.23% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cizzle BiotechnologyN/A -0.23% -31.72% Roquefort Therapeutics -57,057.07%-29.57%-15.86% Do institutionals & insiders hold more shares of CIZ or ROQ? 0.0% of Cizzle Biotechnology shares are owned by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are owned by institutional investors. 72.2% of Cizzle Biotechnology shares are owned by company insiders. Comparatively, 20.3% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, CIZ or ROQ? Cizzle Biotechnology has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. SummaryCizzle Biotechnology beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks. Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROQ vs. The Competition Export to ExcelMetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£2.05M£155.79M£5.75B£2.79BDividend YieldN/A3.78%4.08%5.32%P/E Ratio-181.3341.2983.275,162.88Price / SalesN/A5,361.87535.33101,256.49Price / Cash1.4913.1937.4427.93Price / Book0.3671.5210.556.30Net Income-£1.52M-£90.99M£3.27B£5.89B7 Day Performance4.62%9.96%0.40%0.19%1 Month Performance-15.00%14.01%7.31%50.41%1 Year Performance-64.21%403.82%46.58%154.75% Roquefort Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROQRoquefort TherapeuticsN/AGBX 1.36+4.6%N/A-64.2%£2.05MN/A-181.339News CoverageGap UpCIZCizzle BiotechnologyN/AGBX 1.30-7.1%N/A-18.2%£5.55MN/A-216.674TCFTheracryfN/AGBX 0.23-4.2%N/A-64.6%£5.16MN/A-63.8910Gap UpHigh Trading VolumeEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010GENFGenflow BiosciencesN/AGBX 0.72-4.1%N/A-69.1%£3.40MN/A-151.375Gap UpMTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036DESTDestiny PharmaN/AN/AN/AN/A£2.87M£135.03K-50.0024Gap DownHigh Trading VolumeBSFABSF EnterpriseN/AGBX 1.96-13.1%N/A-53.9%£2.78M£24.09K-137.6812News CoverageHigh Trading VolumeVALValiRxN/AGBX 0.65+13.0%N/A-67.5%£2.15M£49.78K-44.835,450Negative NewsGap UpHigh Trading VolumeRENEReNeuron GroupN/AN/AN/AN/A£1.93M£783K-37.502Gap DownSALVSalvaRx GroupN/AN/AN/AN/A£1.65M£64.50M0.032Gap Up Related Companies and Tools Related Companies CIZ Alternatives TCF Alternatives EVG Alternatives GENF Alternatives MTFB Alternatives DEST Alternatives BSFA Alternatives VAL Alternatives RENE Alternatives SALV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:ROQ) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ROQ Stock Alerts